Search

Your search keyword '"Gryglas-Dworak A"' showing total 32 results
Start Over Author "Gryglas-Dworak A"
32 results on '"Gryglas-Dworak A"'

2. Protocol of a cross-sectional, multicentre and multidisciplinary study describing phenotype and burden of a midfacial segment pain

Author

Marcin Straburzyński, Adrian M Agius, Magdalena Boczarska-Jedynak, Eliza Brożek-Mądry, Karolina Dżaman, Elżbieta Gradek Kwinta, Anna Gryglas-Dworak, Magdalena Nowaczewska, Anshul Sama, Joanna Smardz, Hoo Kee Tsang, Mieszko Więckiewicz, and Marta Waliszewska-Prosół

Subjects
Therapeutics. Pharmacology, RM1-950, Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571
Abstract

Background: Midfacial segment pain is a term used in the past in the diagnosis of patients mainly from ear, nose and throat clinics. This type of pain cannot be attributed to other primary or secondary facial pain, but is to a large extent similar to tension-type headache with midfacial location. The purpose of this study is to describe midfacial segment pain phenotype, burden and comorbidities in a multicentre and multidisciplinary setting. The ultimate goal is a comprehensive description of this type of pain allowing for its implementation in future classifications. Methods: This cross-sectional study is designed to describe midfacial segment pain in a clinical setting. Patients from rhinologic, headache and facial pain or oral medicine/dentistry secondary care centres will be recruited during a 1 year period. Individuals with other facial pain according to current classification such as sinonasal disorders, neoplasms, local infections, history of significant trauma associated with pain onset will be excluded. Data will be collected through a structured questionnaire covering pain characteristics, coexisting diagnoses, pain-related burden and consequences, physical examination and paranasal sinuses imaging.

Published
2024
Full Text
View/download PDF

3. Migraine symptoms, healthcare resources utilization and disease burden in a large Polish migraine cohort

Author

Marta Waliszewska-Prosół, Marcin Straburzyński, Ewa K. Czapińska-Ciepiela, Magdalena Nowaczewska, Anna Gryglas-Dworak, and Sławomir Budrewicz

Subjects
Headache, Quality of life, Abortive treatment, Preventive treatment, Prophylactic treatment, Aura, Medicine
Abstract

Abstract Background The Migraine in Poland study is the first large scale nationwide cross-sectional online survey of symptoms, approaches to management, treatment patterns, quality of life, and sociodemographic characteristics of the Polish migraine patients’ cohort, conducted from August 2021 to June 2022. Methods A cross-sectional online survey was designed based on the American Migraine Prevalence and Prevention (AMPP) Study. Participants were recruited through broad advertisement through various channels. The survey included questions allowing for the diagnosis of migraine without aura (MwoA) based on the third edition of the International Classification of Headache Disorders (ICHD-3). Moreover, the questionnaire assessed sociodemographic and headache features, comorbidities, consultation rates with medical professionals, as well as the use of abortive or preventive treatment, including non-pharmacological methods, psychological symptoms and the burden of migraine. Results A structured online questionnaire was submitted by 3225 respondents aged 13 to 80 (mean age 38.9, 87.1% women). In this group 1679 (52.7%) of participants fulfilled ICHD-3 diagnostic criteria for MwoA, which was in most cases (88.3%) confirmed by a medical professional in the past. In this group the average number of monthly headache days was 4.7, while 47.8% of participants had at least 4 migraine days per month. Mean Migraine Disability Assessment score was 42.65 (median 32). Among MwoA respondents, 1571 (93.6%) had consulted their headache with a medical professional in the past – mostly neurologists (n = 1450 (83.4%) and primary care physicians (n = 1393 (82.9%). In the MwoA cohort, 1553 (92.5%) of participants declared the current use of some form of treatment, although only 193 (11.5%) respondents were currently on preventive medications. The most prevalent comorbidities included: chronic rhinitis (37.1%), allergies (35.9%) and low blood pressure (26.9%). Anxiety (20.4%) and depression (21.3%) were highly prevalent among participants. Conclusions People with migraine in Poland face similar difficulties as their peers in other countries. Despite relatively high access to neurologist consultations and good diagnosis accuracy, migraine still poses diagnostic and therapeutic difficulties. In this context, migraine undertreatment in Polish population must be underlined, especially in context of high disease burden.

Published
2023
Full Text
View/download PDF

4. OnabotulinumtoxinA in elderly patients with chronic migraine: insights from a real-life European multicenter study

Author

Altamura, Claudia, Ornello, R., Ahmed, F., Negro, A., Miscio, A. M., Santoro, A., Alpuente, A., Russo, A., Silvestro, M., Cevoli, S., Brunelli, N., Grazzi, L., Baraldi, C., Guerzoni, S., Andreou, A. P., Lambru, G., Frattale, I., Kamm, K., Ruscheweyh, R., Russo, M., Torelli, P., Filatova, E., Latysheva, N., Gryglas-Dworak, A., Straburzynski, M., Butera, C., Colombo, B., Filippi, M., Pozo-Rosich, P., Martelletti, P., Sacco, S., and Vernieri, F.

Published
2023
Full Text
View/download PDF

5. Sinonasal symptoms in migraine without aura: results from the cross-sectional ‘Migraine in Poland’ study

Author

Marcin Straburzynski, Magdalena Nowaczewska, Ewa K. Czapinska-Ciepiela, Anna Gryglas-Dworak, Slawomir Budrewicz, and Marta Waliszewska-Prosół

Subjects
headache, rhinorrhea, sinusitis, nose, pain, Neurology. Diseases of the nervous system, RC346-429
Abstract

BackgroundMigraine without aura (MwoA) is often mistaken for rhinosinusitis. The purpose of this study was to assess the prevalence of sinonasal symptoms, sinusitis-targeting medication use and burden of migraine in a large group of people with MwoA attacks accompanied by rhinologic symptoms.MethodsData was collected in a cross-sectional online survey based on an adapted population-based study questionnaire. The analysis included the prevalence of rhinorrhea, mucopurulent nasal discharge, nasal congestion, facial pressure and tenderness to palpation, hyposmia/anosmia and osmophobia.Results1,679 (52.73%) MwoA people were identified among 3,225 respondents (women n = 2,809, 87.10%) aged 13–80 years (median age 39; standard deviation 10.4). 1004/1679 (59.8%) migraine patients reported one or more rhinologic symptoms and 341/1679 (20.3%) MwoA respondents had symptoms that met rhinosinusitis clinical diagnostic criteria during their headache attacks. In migraine patients, osmophobia was associated with hyposmia [n = 141 (12.7%) vs. n = 41 (7.2%); p = 0.001] and a sensation of unpleasant smells [n = 216 (19.4%) vs. n = 45 (8.5%); p = 0.001], while facial tenderness to palpation was associated with facial allodynia [n = 532 (50.4%) vs. n = 211 (33.9%); p

Published
2023
Full Text
View/download PDF

6. Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis

Author

Castaldo, Matteo, Waliszewska-Prosół, Marta, Koutsokera, Maria, Robotti, Micaela, Straburzyński, Marcin, Apostolakopoulou, Loukia, Capizzi, Mariarita, Çibuku, Oneda, Ambat, Fidel Dominique Festin, Frattale, Ilaria, Gadzhieva, Zukhra, Gallo, Erica, Gryglas-Dworak, Anna, Halili, Gleni, Jusupova, Asel, Koperskaya, Yana, Leheste, Alo-Rainer, Manzo, Maria Laura, Marcinnò, Andrea, Marino, Antonio, Mikulenka, Petr, Ong, Bee Eng, Polat, Burcu, Popovic, Zvonimir, Rivera-Mancilla, Eduardo, Roceanu, Adina Maria, Rollo, Eleonora, Romozzi, Marina, Ruscitto, Claudia, Scotto di Clemente, Fabrizio, Strauss, Sebastian, Taranta, Valentina, Terhart, Maria, Tychenko, Iryna, Vigneri, Simone, Misiak, Blazej, Martelletti, Paolo, and Raggi, Alberto

Published
2022
Full Text
View/download PDF

7. Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis

Author

Matteo Castaldo, Marta Waliszewska-Prosół, Maria Koutsokera, Micaela Robotti, Marcin Straburzyński, Loukia Apostolakopoulou, Mariarita Capizzi, Oneda Çibuku, Fidel Dominique Festin Ambat, Ilaria Frattale, Zukhra Gadzhieva, Erica Gallo, Anna Gryglas-Dworak, Gleni Halili, Asel Jusupova, Yana Koperskaya, Alo-Rainer Leheste, Maria Laura Manzo, Andrea Marcinnò, Antonio Marino, Petr Mikulenka, Bee Eng Ong, Burcu Polat, Zvonimir Popovic, Eduardo Rivera-Mancilla, Adina Maria Roceanu, Eleonora Rollo, Marina Romozzi, Claudia Ruscitto, Fabrizio Scotto di Clemente, Sebastian Strauss, Valentina Taranta, Maria Terhart, Iryna Tychenko, Simone Vigneri, Blazej Misiak, Paolo Martelletti, Alberto Raggi, and On behalf of the European Headache Federation School of Advanced Studies (EHF-SAS)

Subjects
SARS-CoV-2, COVID-19, Vaccination, Headache, BNT162b2, ChAdOx1, Medicine
Abstract

Abstract Background Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are used to reduce the risk of developing Coronavirus Disease 2019 (COVID-19). Despite the significant benefits in terms of reduced risk of hospitalization and death, different adverse events may present after vaccination: among them, headache is one of the most common, but nowadays there is no summary presentation of its incidence and no description of its main features. Methods We searched PubMed and EMBASE covering the period between January 1st 2020 and August 6th, 2021, looking for record in English and with an abstract and using three main search terms (with specific variations): COVID-19/SARS-CoV-2; Vaccination; headache/adverse events. We selected manuscript including information on subjects developing headache after injection, and such information had to be derived from a structured form (i.e. no free reporting). Pooled estimates and 95% confidence intervals were calculated. Analyses were carried out by vaccine vs. placebo, by first vs. second dose, and by mRNA-based vs. “traditional” vaccines; finally, we addressed the impact of age and gender on post-vaccine headache onset. Results Out of 9338 records, 84 papers were included in the review, accounting for 1.57 million participants, 94% of whom received BNT162b2 or ChAdOx1. Headache was generally the third most common AE: it was detected in 22% (95% CI 18–27%) of subjects after the first dose of vaccine and in 29% (95% CI 23–35%) after the second, with an extreme heterogeneity. Those receiving placebo reported headache in 10–12% of cases. No differences were detected across different vaccines or by mRNA-based vs. “traditional” ones. None of the studies reported information on headache features. A lower prevalence of headache after the first injection of BNT162b2 among older participants was shown. Conclusions Our results show that vaccines are associated to a two-fold risk of developing headache within 7 days from injection, and the lack of difference between vaccine types enable to hypothesize that headache is secondary to systemic immunological reaction than to a vaccine-type specific reaction. Some descriptions report onset within the first 24 h and that in around one-third of the cases, headache has migraine-like features with pulsating quality, phono and photophobia; in 40–60% of the cases aggravation with activity is observed. The majority of patients used some medication to treat headache, the one perceived as the most effective being acetylsalicylic acid.

Published
2022
Full Text
View/download PDF

8. Long‐term reductions in acute headache medication use after eptinezumab treatment in patients with migraine and prior preventive treatment failures: Post hoc analysis of the DELIVER randomized trial.

Author

Gryglas‐Dworak, Anna, Schim, Jack, Ettrup, Anders, Boserup, Line Pickering, Josiassen, Mette Krog, Ranc, Kristina, Sperling, Bjørn, and Ashina, Messoud

Subjects
*MEDICATION abuse, *DISEASE risk factors, *GROUP extensions (Mathematics), *MIGRAINE, *PEPTIDES
Abstract

Objective Background Methods Results Conclusions To evaluate long‐term reductions in acute headache medication (AHM) use with eptinezumab versus placebo in patients with prior preventive migraine treatment failures and medication overuse (MO).Preventive migraine treatment is recommended for patients for whom AHMs have failed and for those who are using excessive amounts of AHM. MO may worsen headache and migraine symptoms in people with migraine; it is a risk factor for disease chronification and/or MO headache.DELIVER was a multicenter, parallel‐group, double‐blind, randomized, placebo‐controlled, phase 3b clinical trial that randomized adults with migraine and two to four prior preventive failures to eptinezumab 100 mg, 300 mg, or placebo infusion every 12 weeks; patients initially given placebo received eptinezumab 100 mg or 300 mg in the extension period. MO was defined according to diagnostic criteria for MO headache in the baseline diary reports. This post hoc analysis of the DELIVER study included change from baseline in AHM days/month of use (ergotamines, triptans, simple or combination analgesics, and opioids; total and select class‐specific use) in the MO population.A total of 890 patients were included in the total population, and 438/890 (49.2%) had MO at baseline. In both the total population and MO population, eptinezumab resulted in greater reductions in total AHM days/month of use during weeks 1–24 than placebo, with triptans showing the largest reduction among AHM classes. Patients switching from placebo to eptinezumab experienced reductions in AHM days/month similar to that of initial eptinezumab treatment. In the extension population, mean (standard error [SE]) changes from baseline in AHM days/month were −4.6 (0.32; 100 mg) and −4.8 (0.32; 300 mg) across weeks 1–4 in patients who received eptinezumab for the entire treatment period and were −4.8 (0.44; placebo–100 mg) and −5.5 (0.44; placebo–300 mg) across weeks 25–28 in patients who switched from placebo to eptinezumab. Mean (SE) changes from baseline in AHM days/month in the extension MO population were −6.5 (0.59; 100 mg) and −6.6 (0.57; 300 mg) across weeks 1–4 in patients who received eptinezumab for the entire treatment period and were −7.1 (0.81; 100 mg) and −8.0 (0.80; 300 mg) across weeks 25–28 in patients who were switched from placebo to eptinezumab. All treatment arms sustained or further reduced AHM use across 18 months of trial participation. Across weeks 1–4, in patients fulfilling criteria for MO at baseline, 68.0% (102/150) of patients treated with eptinezumab 100 mg and 74.7% (109/146) of patients treated with eptinezumab 300 mg reported AHM use below MO thresholds compared to 43.3% (61/141) of patients receiving placebo. In patients with MO at baseline, the proportion of patients without MO remained above 60.0% for all treatment groups during the extension period.Eptinezumab reduced total AHM use more than placebo in patients with prior preventive failures and in patients with MO at baseline; largest reductions were observed for triptans. Robust reductions in AHM use after eptinezumab were sustained or further reduced with up to 18 months of treatment, and most patients no longer met thresholds for MO. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Is There a Gender Difference in the Response to onabotulinumtoxinA in Chronic Migraine? Insights from a Real-Life European Multicenter Study on 2879 Patients

Author

Ornello, Raffaele, Ahmed, Fayyaz, Negro, Andrea, Miscio, Anna Maria, Santoro, Antonio, Alpuente, Alicia, Russo, Antonio, Silvestro, Marcello, Cevoli, Sabina, Brunelli, Nicoletta, Vernieri, Fabrizio, Grazzi, Licia, Baraldi, Carlo, Guerzoni, Simona, Andreou, Anna P., Lambru, Giorgio, Kamm, Katharina, Ruscheweyh, Ruth, Russo, Marco, Torelli, Paola, Filatova, Elena, Latysheva, Nina, Gryglas-Dworak, Anna, Straburzyński, Marcin, Butera, Calogera, Colombo, Bruno, Filippi, Massimo, Pozo-Rosich, Patricia, Martelletti, Paolo, and Sacco, Simona

Published
2021
Full Text
View/download PDF

11. Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine: Insights from a Real-Life European Multicenter Study

Author

Ornello, Raffaele, Ahmed, Fayyaz, Negro, Andrea, Miscio, Anna Maria, Santoro, Antonio, Alpuente, Alicia, Russo, Antonio, Silvestro, Marcello, Cevoli, Sabina, Brunelli, Nicoletta, Vernieri, Fabrizio, Grazzi, Licia, Baraldi, Carlo, Guerzoni, Simona, Andreou, Anna P., Lambru, Giorgio, Frattale, Ilaria, Kamm, Katharina, Ruscheweyh, Ruth, Russo, Marco, Torelli, Paola, Filatova, Elena, Latysheva, Nina, Gryglas-Dworak, Anna, Straburzynski, Marcin, Butera, Calogera, Colombo, Bruno, Filippi, Massimo, Pozo-Rosich, Patricia, Martelletti, Paolo, and Sacco, Simona

Published
2021
Full Text
View/download PDF

12. InterMiG: international differences in the therapeutic approach to migraine patients in specialized headache centers

Author

AB Gago-Veiga, J-I Huhn, N Latysheva, A Vieira Campos, M Torres-Ferrus, A Alpuente Ruiz, S Sacco, I Frattale, R Ornello, R Ruscheweyh, IB Marques, A Gryglas-Dworak, C Stark, VJ Gallardo, and P Pozo-Rosich

Subjects
Migraine, Preventive treatment, International, Differences, Antidepressant, Antiepileptic, Medicine
Abstract

Abstract Background There is currently a wide therapeutic arsenal for migraine patients, without a single first-line preventive drug and we choose the different available alternatives taking into account comorbidities, national guidelines, previous treatments and personal experiences. Our objective was to evaluate the differences in the use of migraine treatments between neurologists from different countries. Methods This is a multi-centre observational study carried out by neurologists from specialized headache units in seven countries, retrospective with consecutive inclusion of all patients presenting with a migraine diagnosis, over a period of three months. Results A total of 734 patients were recruited but only 600 were considered in the analysis in order to homogenize the patient cohorts from countries: 200 Spain (ES), 100 Italy (IT), 85 Russia (RUS), 80 Germany (DE), 60 Portugal (PT), 45 Poland (PL) and 30 Australia (AU). 85.4 % of patients were women with a mean age of 42.6 ± 11.8 years. Considering previous and current preventive treatment, the order of use was: antidepressants (69.3 %), antiepileptic drugs (54.7 %), beta-blockers and antihypertensive drugs (49.7 %), OnabotulinumtoxinA (44.0 %) and others (36.2 %). Statistically significant differences were found between all pharmacological classes: antidepressants were commonly used in all countries, with the exception of Poland (AU: 76.7 %, IT: 71.0 %, DE: 60.0 %, PL: 31.1 %, PT: 71.7 %, RUS: 70.6 %, ES: 78.5 %; p

Published
2021
Full Text
View/download PDF

14. Is There a Gender Difference in the Response to onabotulinumtoxinA in Chronic Migraine? Insights from a Real-Life European Multicenter Study on 2879 Patients

Author

Simona Guerzoni, Nicoletta Brunelli, Simona Sacco, N. V. Latysheva, Paolo Martelletti, Raffaele Ornello, Carlo Baraldi, Alicia Alpuente, Patricia Pozo-Rosich, Marco Russo, Bruno Colombo, Calogera Butera, Antonio Russo, Giorgio Lambru, Anna Gryglas-Dworak, S. Cevoli, Marcin Straburzyński, Ruth Ruscheweyh, Andrea Negro, Anna Maria Miscio, Marcello Silvestro, Fayyaz Ahmed, Katharina Kamm, Licia Grazzi, Massimo Filippi, Elena Filatova, Fabrizio Vernieri, Antonio Santoro, Paola Torelli, Anna P. Andreou, Ornello, R., Ahmed, F., Negro, A., Miscio, A. M., Santoro, A., Alpuente, A., Russo, A., Silvestro, M., Cevoli, S., Brunelli, N., Vernieri, F., Grazzi, L., Baraldi, C., Guerzoni, S., Andreou, A. P., Lambru, G., Kamm, K., Ruscheweyh, R., Russo, M., Torelli, P., Filatova, E., Latysheva, N., Gryglas-Dworak, A., Straburzynski, M., Butera, C., Colombo, B., Filippi, M., Pozo-Rosich, P., Martelletti, P., Sacco, S., Institut Català de la Salut, [Ornello R] Neuroscience Section, Department of Applied Clinical Sciences and Biotechnology, University of L’Aquila, 67100 L’Aquila, Italy. [Ahmed F] Department of Neurosciences, Hull University Teaching Hospitals, Hull, UK. [Negro A] Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sant’Andrea Hospital, Sapienza University, 00189 Rome, RM, Italy. [Miscio AM, Santoro A] Unit of Neurology, Headache Center, Fondazione IRCCS ‘‘Casa Sollievo della Sofferenza’’, San Giovanni Rotondo, FG, Italy. [Alpuente A, Pozo-Rosich P] Unitat de Cefalea, Servei de Neurologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca en Cefalees i Dolors Neurològics, Servei de Medicina, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
medicine.medical_specialty, enfermedades del sistema nervioso::enfermedades del sistema nervioso central::enfermedades cerebrales::trastornos con cefaleas::cefaleas primarias::trastornos migrañosos [ENFERMEDADES], Migranya - Efecte dels medicaments, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Migranya - Tractament, Other subheadings::Other subheadings::/drug therapy [Other subheadings], law.invention, Chronic Migraine, Randomized controlled trial, law, OnabotulinumtoxinA, Internal medicine, Statistical significance, medicine, Gender difference, Adverse effect, Nervous System Diseases::Central Nervous System Diseases::Brain Diseases::Headache Disorders::Headache Disorders, Primary::Migraine Disorders [DISEASES], Migraine, Original Research, Chronic migraine, Men, business.industry, diagnóstico::pronóstico::resultado del tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Diagnosis::Prognosis::Treatment Outcome [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], medicine.disease, Anesthesiology and Pain Medicine, Propensity score matching, Cohort, Avaluació de resultats (Assistència sanitària), Observational study, Neurology (clinical), business
Abstract

Migranya crònica; Diferència de gènere; OnabotulinumtoxinA Migraña crónica; Diferencia de género, OnabotulinumtoxinA Chronic migraine; Gender difference; OnabotulinumtoxinA Introduction Migraine is mostly a female disorder because of its lower prevalence in men. Less than 20% of patients included in the available studies on migraine treatments are men; hence, the evidence on migraine treatments might not apply to men. The aims of the present study were to provide reliable information on the effectiveness of onabotulinumtoxinA (BT-A) for chronic migraine in men and to compare clinical benefits between men and women. Methods We performed a pooled patient-level gender-specific analysis of real-life data on BT-A for chronic migraine of patients followed-up to 9 months. We reported the 50% responder rates during each BT-A cycle, defined as percentage of reduction in monthly headache days (MHDs) compared to baseline, along with 75% and 30% responder rates. We also reported the mean decrease in MHDs and in days of acute medication use (DAMs) during each BT-A cycle as compared to baseline. We also evaluated the reasons for stopping the treatment within the third cycle. Results We included an overall cohort of 2879 patients, 522 of whom (18.1%) were men. In men, 50% responder rates were 27.7% during the first BT-A cycle, 29.2% during the second, and 35.6% during the third cycle; in women, the corresponding rates were 26.6%, 33.5%, and 41.0%. In the overall cohort, responder rates did not differ between men and women during the first two cycles; during the third cycle, the distribution was different (P

Published
2021
Full Text
View/download PDF

15. Etiology of ‘Sinus Headache’—Moving the Focus from Rhinology to Neurology. A Systematic Review

Author

Marcin Straburzyński, Anna Gryglas-Dworak, Magdalena Nowaczewska, Eliza Brożek-Mądry, and Paolo Martelletti

Subjects
sinus headache, migraine, tension-type headache, sinusitis, facial pain, midfacial segment pain, Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571
Abstract

‘Sinus headache and/or facial pain’ (SH) is a common complaint encountered by otorhinolaryngologists, neurologists and general practitioners. However, several studies suggested that the majority of those cases may be attributed to primary headaches (i.e., migraine and tension-type headache (TTH). The purpose of this review is to evaluate the etiology of SH. The first part includes cross-sectional studies analyzing the prevalence of respective diagnoses in subjects with SH. The majority of these publications indicate that migraine and TTH are the most prevalent causes of SH, although most of these studies were conducted in a clinical setting. The second part of this review included treatment trials in subjects with SH. The findings from this part of the review show that SH without rhinosinusitis responds well to pharmacotherapy targeted at primary headaches. This observation further supports a neurologic etiology of the majority of SH cases.

Published
2021
Full Text
View/download PDF

16. OnabotulinumtoxinA in elderly patients with chronic migraine: insights from a real-life European multicenter study

Author

Altamura, Claudia, primary, Ornello, R., additional, Ahmed, F., additional, Negro, A., additional, Miscio, A. M., additional, Santoro, A., additional, Alpuente, A., additional, Russo, A., additional, Silvestro, M., additional, Cevoli, S., additional, Brunelli, N., additional, Grazzi, L., additional, Baraldi, C., additional, Guerzoni, S., additional, Andreou, A. P., additional, Lambru, G., additional, Frattale, I., additional, Kamm, K., additional, Ruscheweyh, R., additional, Russo, M., additional, Torelli, P., additional, Filatova, E., additional, Latysheva, N., additional, Gryglas-Dworak, A., additional, Straburzynski, M., additional, Butera, C., additional, Colombo, B., additional, Filippi, M., additional, Pozo-Rosich, P., additional, Martelletti, P., additional, Sacco, S., additional, and Vernieri, F., additional

Published
2022
Full Text
View/download PDF

17. Excellent Response to OnabotulinumtoxinA: Different Definitions, Different Predictors

Author

Ornello, Raffaele, primary, Baraldi, Carlo, additional, Ahmed, Fayyaz, additional, Negro, Andrea, additional, Miscio, Anna Maria, additional, Santoro, Antonio, additional, Alpuente, Alicia, additional, Russo, Antonio, additional, Silvestro, Marcello, additional, Cevoli, Sabina, additional, Brunelli, Nicoletta, additional, Vernieri, Fabrizio, additional, Grazzi, Licia, additional, Pani, Luca, additional, Andreou, Anna, additional, Lambru, Giorgio, additional, Frattale, Ilaria, additional, Kamm, Katharina, additional, Ruscheweyh, Ruth, additional, Russo, Marco, additional, Torelli, Paola, additional, Filatova, Elena, additional, Latysheva, Nina, additional, Gryglas-Dworak, Anna, additional, Straburzyński, Marcin, additional, Butera, Calogera, additional, Colombo, Bruno, additional, Filippi, Massimo, additional, Pozo-Rosich, Patricia, additional, Martelletti, Paolo, additional, Guerzoni, Simona, additional, and Sacco, Simona, additional

Published
2022
Full Text
View/download PDF

18. Excellent Response to OnabotulinumtoxinA : Different Definitions, Different Predictors

Author

Ornello, Raffaele, Baraldi, Carlo, Ahmed, Fayyaz, Negro, Andrea, Miscio, Anna Maria, Santoro, Antonio, Alpuente, Alicia, Russo, Antonio, Silvestro, Marcello, Cevoli, Sabina, Brunelli, Nicoletta, Vernieri, Fabrizio, Grazzi, Licia, Pani, Luca, Andreou, Anna P, Lambru, Giorgio, Frattale, Ilaria, Kamm, Katharina, Ruscheweyh, Ruth, Russo, Marco, Torelli, Paola, Filatova, Elena, Latysheva, Nina, Gryglas-Dworak, Anna, Straburzyński, Marcin, Butera, Calogera, Colombo, Bruno, Filippi, Massimo, Pozo-Rosich, Patricia, Martelletti, Paolo, Guerzoni, Simona, Sacco, Simona, Universitat Autònoma de Barcelona, Ornello, Raffaele, Baraldi, Carlo, Ahmed, Fayyaz, Negro, Andrea, Miscio, Anna Maria, Santoro, Antonio, Alpuente, Alicia, Russo, Antonio, Silvestro, Marcello, Cevoli, Sabina, Brunelli, Nicoletta, Vernieri, Fabrizio, Grazzi, Licia, Pani, Luca, Andreou, Anna, Lambru, Giorgio, Frattale, Ilaria, Kamm, Katharina, Ruscheweyh, Ruth, Russo, Marco, Torelli, Paola, Filatova, Elena, Latysheva, Nina, Gryglas-Dworak, Anna, Straburzyński, Marcin, Butera, Calogera, Colombo, Bruno, Filippi, Massimo, Pozo-Rosich, Patricia, Martelletti, Paolo, Guerzoni, Simona, Sacco, Simona, Institut Català de la Salut, [Ornello R] Neuroscience Section, Department of Applied Clinical Sciences and Biotechnology, University of L’Aquila, L’Aquila, Italy. [Baraldi C] Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, Department of Specialist Medicines, AOU Policlinico di Modena, Modena, Italy. [Ahmed F] Department of Neurosciences, Hull University Teaching Hospitals, Hull, UK. [Negro A] Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sant’Andrea Hospital, Sapienza University, Rome, Italy. [Miscio AM, Santoro A] Headache Center, Unit of Neurology, Fondazione IRCCS 'Casa Sollievo Della Sofferenza', San Giovanni Rotondo, Italy. [Alpuente A, Pozo-Rosich P] Unitat de Cefalea, Servei de Neurologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca en Cefalea i Dolor Neurològic, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
chronic migraine, onabotulinumtoxinA, predictors of response, excellent responders, Botulinum Toxins, enfermedades del sistema nervioso::enfermedades del sistema nervioso central::enfermedades cerebrales::trastornos con cefaleas::cefaleas primarias::trastornos migrañosos [ENFERMEDADES], Health, Toxicology and Mutagenesis, Migraine Disorders, Excellent responders, acciones y usos químicos::acciones tóxicas::noxas::neurotoxinas [COMPUESTOS QUÍMICOS Y DROGAS], Predictors of response, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Migranya - Tractament, Other subheadings::Other subheadings::/drug therapy [Other subheadings], Type A, Neurotoxines - Ús terapèutic, Humans, Chemical Actions and Uses::Toxic Actions::Noxae::Neurotoxins [CHEMICALS AND DRUGS], Other subheadings::/therapeutic use [Other subheadings], Botulinum Toxins, Type A, Nervous System Diseases::Central Nervous System Diseases::Brain Diseases::Headache Disorders::Headache Disorders, Primary::Migraine Disorders [DISEASES], Chronic migraine, Otros calificadores::/uso terapéutico [Otros calificadores], Chronic Disease, Female, Headache, Treatment Outcome, Public Health, Environmental and Occupational Health, Onabotulinumtoxina, Avaluació de resultats (Assistència sanitària)
Abstract

Chronic migraine; OnabotulinumtoxinA; Predictors of response Migraña crónica; OnabotulinumtoxinA; Predictores de respuesta Migranya crònica; OnabotulinumtoxinA; Predictors de resposta The identification of patients who can benefit the most from the available preventive treatments is important in chronic migraine. We explored the rate of excellent responders to onabotulinumtoxinA in a multicenter European study and explored the predictors of such response, according to different definitions. A pooled analysis on chronic migraineurs treated with onabotulinumtoxinA and followed-up for, at least, 9 months was performed. Excellent responders were defined either as patients with a ≥75% decrease in monthly headache days (percent-based excellent responders) or as patients with

Published
2022
Full Text
View/download PDF

19. Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine: Insights from a Real-Life European Multicenter Study

Author

Katharina Kamm, Anna Gryglas-Dworak, N. V. Latysheva, Simona Guerzoni, Licia Grazzi, Marco Russo, Anna Maria Miscio, Paolo Martelletti, Patricia Pozo-Rosich, Simona Sacco, Marcin Straburzyński, Sabina Cevoli, Alicia Alpuente, Carlo Baraldi, Ilaria Frattale, Giorgio Lambru, Elena Filatova, Calogera Butera, Antonio Russo, Marcello Silvestro, Ruth Ruscheweyh, Antonio Santoro, Fabrizio Vernieri, Andrea Negro, Paola Torelli, Fayyaz Ahmed, Anna P. Andreou, Massimo Filippi, Bruno Colombo, Nicoletta Brunelli, Raffaele Ornello, Institut Català de la Salut, [Ornello R] Neuroscience Section, Department of Applied Clinical Sciences and Biotechnology, University of L’Aquila, Via Vetoio 1 Coppito, 67100 L’Aquila, Italy. [Ahmed F] Department of Neurosciences, Hull University Teaching Hospitals, Hull, UK. [Negro A] Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sant’Andrea Hospital, Sapienza University, 00189 Rome, RM, Italy. [Miscio AM, Santoro A] Headache Center, Unit of Neurology, Fondazione IRCCS ‘‘Casa Sollievo Della Sofferenza’’, San Giovanni Rotondo, Foggia, Italy. [Alpuente A, Pozo-Rosich P] Unitat de Cefalea, Servei de Neurologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca en Cefalea i Dolor Neurològic, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
medicine.medical_specialty, Multivariate analysis, enfermedades del sistema nervioso::enfermedades del sistema nervioso central::enfermedades cerebrales::trastornos con cefaleas::cefaleas primarias::trastornos migrañosos [ENFERMEDADES], Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Migranya - Tractament, Other subheadings::Other subheadings::/drug therapy [Other subheadings], Chronic Migraine, Malalties cròniques - Tractament, OnabotulinumtoxinA, Internal medicine, Partial response, medicine, Retrospective analysis, Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Chronic Disease [DISEASES], In patient, Nervous System Diseases::Central Nervous System Diseases::Brain Diseases::Headache Disorders::Headache Disorders, Primary::Migraine Disorders [DISEASES], Chronic migraine, Real-life evidence, Multicenter study, business.industry, afecciones patológicas, signos y síntomas::procesos patológicos::atributos de la enfermedad::enfermedad crónica [ENFERMEDADES], Anesthesiology and Pain Medicine, Neurology (clinical), business
Abstract

Migranya crònica; Estudi multicèntric; Evidència de la vida real Migraña crónica; Estudio multicéntrico; Evidencia de la vida real Chronic migraine; Multicenter study; Real-life evidence Introduction OnabotulinumtoxinA (BT-A) quarterly was the first treatment approved specifically for chronic migraine (CM). It is unclear whether three cycles are better than two to assess early BT-A response. Methods We performed a retrospective analysis on real-life prospectively collected data in 16 European headache centers. All the centers provided data on patients treated with BT-A for CM over the first three cycles of treatment. For each treatment cycle we defined patients as “good responders” if reporting a ≥ 50% reduction in monthly headache days compared with the three months before starting BT-A, “partial responders” if reporting a 30–49% reduction in monthly headache days, and “non-responders” if reporting a

Published
2021
Full Text
View/download PDF

20. Headache onset after vaccination against SARS-CoV-2:a systematic literature review and meta-analysis

Author

Castaldo, Matteo, Waliszewska-Prosół, Marta, Koutsokera, Maria, Robotti, Micaela, Straburzyński, Marcin, Apostolakopoulou, Loukia, Capizzi, Mariarita, Çibuku, Oneda, Ambat, Fidel Dominique Festin, Frattale, Ilaria, Gadzhieva, Zukhra, Gallo, Erica, Gryglas-Dworak, Anna, Halili, Gleni, Jusupova, Asel, Koperskaya, Yana, Leheste, Alo Rainer, Manzo, Maria Laura, Marcinnò, Andrea, Marino, Antonio, Mikulenka, Petr, Ong, Bee Eng, Polat, Burcu, Popovic, Zvonimir, Rivera-Mancilla, Eduardo, Roceanu, Adina Maria, Rollo, Eleonora, Romozzi, Marina, Ruscitto, Claudia, Scotto di Clemente, Fabrizio, Strauss, Sebastian, Taranta, Valentina, Terhart, Maria, Tychenko, Iryna, Vigneri, Simone, Misiak, Blazej, Martelletti, Paolo, Raggi, Alberto, Castaldo, Matteo, Waliszewska-Prosół, Marta, Koutsokera, Maria, Robotti, Micaela, Straburzyński, Marcin, Apostolakopoulou, Loukia, Capizzi, Mariarita, Çibuku, Oneda, Ambat, Fidel Dominique Festin, Frattale, Ilaria, Gadzhieva, Zukhra, Gallo, Erica, Gryglas-Dworak, Anna, Halili, Gleni, Jusupova, Asel, Koperskaya, Yana, Leheste, Alo Rainer, Manzo, Maria Laura, Marcinnò, Andrea, Marino, Antonio, Mikulenka, Petr, Ong, Bee Eng, Polat, Burcu, Popovic, Zvonimir, Rivera-Mancilla, Eduardo, Roceanu, Adina Maria, Rollo, Eleonora, Romozzi, Marina, Ruscitto, Claudia, Scotto di Clemente, Fabrizio, Strauss, Sebastian, Taranta, Valentina, Terhart, Maria, Tychenko, Iryna, Vigneri, Simone, Misiak, Blazej, Martelletti, Paolo, and Raggi, Alberto

Abstract

Background: Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are used to reduce the risk of developing Coronavirus Disease 2019 (COVID-19). Despite the significant benefits in terms of reduced risk of hospitalization and death, different adverse events may present after vaccination: among them, headache is one of the most common, but nowadays there is no summary presentation of its incidence and no description of its main features. Methods: We searched PubMed and EMBASE covering the period between January 1st 2020 and August 6th, 2021, looking for record in English and with an abstract and using three main search terms (with specific variations): COVID-19/SARS-CoV-2; Vaccination; headache/adverse events. We selected manuscript including information on subjects developing headache after injection, and such information had to be derived from a structured form (i.e. no free reporting). Pooled estimates and 95% confidence intervals were calculated. Analyses were carried out by vaccine vs. placebo, by first vs. second dose, and by mRNA-based vs. “traditional” vaccines; finally, we addressed the impact of age and gender on post-vaccine headache onset. Results: Out of 9338 records, 84 papers were included in the review, accounting for 1.57 million participants, 94% of whom received BNT162b2 or ChAdOx1. Headache was generally the third most common AE: it was detected in 22% (95% CI 18–27%) of subjects after the first dose of vaccine and in 29% (95% CI 23–35%) after the second, with an extreme heterogeneity. Those receiving placebo reported headache in 10–12% of cases. No differences were detected across different vaccines or by mRNA-based vs. “traditional” ones. None of the studies reported information on headache features. A lower prevalence of headache after the first injection of BNT162b2 among older participants was shown. Conclusions: Our results show that vaccines are associated to a two-fold risk of developing hea

Published
2022

21. Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis

Author

Castaldo, M. Waliszewska-Prosół, M. Koutsokera, M. Robotti, M. Straburzyński, M. Apostolakopoulou, L. Capizzi, M. Çibuku, O. Ambat, F.D.F. Frattale, I. Gadzhieva, Z. Gallo, E. Gryglas-Dworak, A. Halili, G. Jusupova, A. Koperskaya, Y. Leheste, A.-R. Manzo, M.L. Marcinnò, A. Marino, A. Mikulenka, P. Ong, B.E. Polat, B. Popovic, Z. Rivera-Mancilla, E. Roceanu, A.M. Rollo, E. Romozzi, M. Ruscitto, C. Scotto di Clemente, F. Strauss, S. Taranta, V. Terhart, M. Tychenko, I. Vigneri, S. Misiak, B. Martelletti, P. Raggi, A. On behalf of the European Headache Federation School of Advanced Studies (EHF-SAS)

Abstract

Background: Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are used to reduce the risk of developing Coronavirus Disease 2019 (COVID-19). Despite the significant benefits in terms of reduced risk of hospitalization and death, different adverse events may present after vaccination: among them, headache is one of the most common, but nowadays there is no summary presentation of its incidence and no description of its main features. Methods: We searched PubMed and EMBASE covering the period between January 1st 2020 and August 6th, 2021, looking for record in English and with an abstract and using three main search terms (with specific variations): COVID-19/SARS-CoV-2; Vaccination; headache/adverse events. We selected manuscript including information on subjects developing headache after injection, and such information had to be derived from a structured form (i.e. no free reporting). Pooled estimates and 95% confidence intervals were calculated. Analyses were carried out by vaccine vs. placebo, by first vs. second dose, and by mRNA-based vs. “traditional” vaccines; finally, we addressed the impact of age and gender on post-vaccine headache onset. Results: Out of 9338 records, 84 papers were included in the review, accounting for 1.57 million participants, 94% of whom received BNT162b2 or ChAdOx1. Headache was generally the third most common AE: it was detected in 22% (95% CI 18–27%) of subjects after the first dose of vaccine and in 29% (95% CI 23–35%) after the second, with an extreme heterogeneity. Those receiving placebo reported headache in 10–12% of cases. No differences were detected across different vaccines or by mRNA-based vs. “traditional” ones. None of the studies reported information on headache features. A lower prevalence of headache after the first injection of BNT162b2 among older participants was shown. Conclusions: Our results show that vaccines are associated to a two-fold risk of developing headache within 7 days from injection, and the lack of difference between vaccine types enable to hypothesize that headache is secondary to systemic immunological reaction than to a vaccine-type specific reaction. Some descriptions report onset within the first 24 h and that in around one-third of the cases, headache has migraine-like features with pulsating quality, phono and photophobia; in 40–60% of the cases aggravation with activity is observed. The majority of patients used some medication to treat headache, the one perceived as the most effective being acetylsalicylic acid. © 2022, The Author(s).

Published
2022

22. Additional file 1 of Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis

Author

Castaldo, Matteo, Waliszewska-Prosół, Marta, Koutsokera, Maria, Robotti, Micaela, Straburzyński, Marcin, Apostolakopoulou, Loukia, Capizzi, Mariarita, Çibuku, Oneda, Ambat, Fidel Dominique Festin, Frattale, Ilaria, Gadzhieva, Zukhra, Gallo, Erica, Gryglas-Dworak, Anna, Halili, Gleni, Jusupova, Asel, Koperskaya, Yana, Leheste, Alo-Rainer, Manzo, Maria Laura, Marcinnò, Andrea, Marino, Antonio, Mikulenka, Petr, Ong, Bee Eng, Polat, Burcu, Popovic, Zvonimir, Rivera-Mancilla, Eduardo, Roceanu, Adina Maria, Rollo, Eleonora, Romozzi, Marina, Ruscitto, Claudia, Scotto di Clemente, Fabrizio, Strauss, Sebastian, Taranta, Valentina, Terhart, Maria, Tychenko, Iryna, Vigneri, Simone, Misiak, Blazej, Martelletti, Paolo, and Raggi, Alberto

Subjects
Data_FILES
Abstract

Additional file 1.

Published
2022
Full Text
View/download PDF

23. Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European MigraineHeadache Alliance

Author

Sacco S., Lampl C., Maassen van den Brink A., Caponnetto V., Braschinsky M., Ducros A., Little P., Pozo-Rosich P., Reuter U., Ruiz de la Torre E., Sanchez Del Rio M., Sinclair A. J., Martelletti P., Katsarava Z., Cakciri G., Djamandi P., Grabova S., Halili G., Kruja J., Kuqo A., Naco D., Quka A., Stefanidhi L., Vyshka G., Zekja I., Bruera O., Gomez D., Guitian B., Roma J. C., Chen I. L., Bashirova S., Linkov M., Van Den Abbeele D., Vanderschueren G., Araujo R., Arruda R., Catharino A., Ciriaco J., Dalla Corte A., Dornas R., Felsenfeld B., Fonseca Taufner A., Fragoso Y., Hurtado R., Isoni Martins D., Londero R., Melo L., Mignoni K. S., Sgobbi De Souza P. V., Souza M. N., Osman S., Baltzer V., Pacheco Mosquera L. F., Dubroja I., Hucika Z., Lisak M., Lovrencic-Huzjan A., Lusic I., Mahovic Lakusic D., Mikulenka P., Rehulka P., Amin F. M., Antic S., Fakhril-Din Z., Moeller-Hansen J., Munksgaard S., Nan A. M., Pellesi L., Schytz H., Vides M., Braschinsky K., Krikmann U., Roos C., Cauchie A., Christian L., Guegan-Massardier E., Demarquay G., Gilles G., Mawet J., Kuhn E., Lanteri Minet M., Bustuchina Vlaicu M., Moisset X., Muresan M., Najjar-Ravan M., Giraud P., Simonin S., De Gaalon S., Chakhava G., Demuria M., Gegelashvili G., Kapanadze N., Antonakakis A., Gaul C., Forderreuther S., Huhn J. -I., Ibragimov S., Kamm K., Raffaelli B., Czaniera R., Ruscheweyh R., Gavanozi E., Karagiorgis G., Mavridism T., Ertsey C., Shubham D., Callista Tanowi A. D., Erdana Putra S., Hadi D. W., Kurnia L., Nasrul M., Albanese M., Antonaci F., Asioli G. M., Baschi R., Bentivegna E., Brunelli N., Caratozzolo S., Catarci T., Cherchi A., Corbelli I., Costa A., De Luca C., Doretti A., Favoni V., Ghiotto N., Giamberardino M. A., Giani L., Zanchin G., Govone F., Grillo G., Mampreso E., Negro A., Ornello R., Pasculli M., Pensato U., Prudenzano M. P. A., Quintana S., Rapisarda R., Romoli M., Russo A., Russo M., Spuntarelli V., Tiseo C., Torrente A., Vacca A., Vaula G., Vigano A., Vigneri S., Freimane A., Slosberga E., Zvaune L., Tan H. J., Fenech C., Cobilt-Catana R., De La Garza Neme Y., Martinez M., Proano Narvaez J. V., Rodriguez Herrera A., Vazquez D., Grosu O., Jakupi A., Kristoffersen E. S., Tronvik E., Winsvold B. S., Azhar M., Reyes Alvarez M. T., Vilchez Fernandez L., Dayrit G. D., Czapinska-Ciepiela E. K., Fila M., Gryglas-Dworak A., Couto M., Esperanca P., Ferreira A., Gil-Gouveia R., Goncalves A., Lopes M., Lourenco M., Machado J., Marinho M., Miranda M. A., Palavra F., Parreira E., Pavao Martins I., Pereira L., Pereira Monteiro J. M., Leahu P., Aloman S., Abramova E., Akhmadeeva L., Belopasova A., Bogdanova I., Chernyak M., Epifanova M., Fedorova E., Felbush A., Karpova M., Korobkova D., Korotkova D., Latysheva N., Makeeva T., Mikhalkina K., Osipova V., Roshchina O., Serga A., Serousova O. V., Sidorova Y., Skiba I., Skorobogatykh K., Vashchenko N., Apostolski S., Buder N., Kopitovic A., Mirjana J., Podgorac A., Rakic D., Simic S., Zarko M., Trajkovic J. Z., Beltran-Blasco I., Calabria Gallego M. D., Diaz Insa S., Ezpeleta D., Fernandez M., Garcia-Azorin D., Gonzalez-Garcia N., Guerrero A. L., Guillamon E., Herreros Rodriguez J., Layos-Romero A., Medrano V., Minguez-Olaondo A., Navarro Munoz S., Pare Curell M., Ruibal M., Sanchez Alvarez J. M., Santos S., Soler R., Viguera J., Zabalza R., Abdelrahman T., Abobaker Hamza S. B., Mustafa M. N., Edvinsson L., Gantenbein A., Maraffi I., Couturier E., Dirkx T., Hoebert M., Van Oosterhout W., Wim M., Zwartbol R., Bakir M., Demirel H., Erdemoglu A. K., Ertem D. H., Gonullu S., Ilgaz Aydinlar E., Inan L. E., Olmez B., Ozbenli T., Ozge A., Uluduz D., Uyar Cankay T., Yalinay Dikmen P., Saxena A. B., Bozhenko M., Bozhenko N., Bubnov R., Tsurkalenko O., Abu-Arafeh I., Idrovo L., Miller S., Nirmalananthan N., Sinclair A., Taleti E., Valori A., Whitehouse W., Zermansky A., Thura M., Institut Català de la Salut, [Sacco S, Caponnetto V] Neuroscience section – Department of Biotechnological and Applied Clinical Sciences and (Edificio Coppito 2), University of L’Aquila, Via Vetoio, 67100 L’Aquila, Italy. Regional Referral Headache Center of the Abruzzo Region, ASL Avezzano-Sulmona-L’Aquila, L’Aquila, Italy. [Lampl C] Department of Neurology, Headache Medical Centre Linz, Hospital Barmherzige Brüder, Centre of Integrative Medicine (ZiAM) Ordensklinikum Linz, Linz, Austria. [Maassen van den Brink A] Division of Pharmacology, Department of Internal Medicine, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands. [Braschinsky M] Headache Clinic, Department of Neurology, Tartu University Clinics, Tartu, Estonia. [Ducros A] Headache Unit, Neurology Department, Montpellier University Hospital and Montpellier University, Montpellier, France. [Pozo-Rosich P] Unitat de Cefalea, Servei de Neurologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Grup d'Investigació en Cefalees i Dolors Neurològics, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, Sacco, S., Lampl, C., Maassen van den Brink, A., Caponnetto, V., Braschinsky, M., Ducros, A., Little, P., Pozo-Rosich, P., Reuter, U., Ruiz de la Torre, E., Sanchez Del Rio, M., Sinclair, A. J., Martelletti, P., Katsarava, Z., Cakciri, G., Djamandi, P., Grabova, S., Halili, G., Kruja, J., Kuqo, A., Naco, D., Quka, A., Stefanidhi, L., Vyshka, G., Zekja, I., Bruera, O., Gomez, D., Guitian, B., Roma, J. C., Chen, I. L., Bashirova, S., Linkov, M., Van Den Abbeele, D., Vanderschueren, G., Araujo, R., Arruda, R., Catharino, A., Ciriaco, J., Dalla Corte, A., Dornas, R., Felsenfeld, B., Fonseca Taufner, A., Fragoso, Y., Hurtado, R., Isoni Martins, D., Londero, R., Melo, L., Mignoni, K. S., Sgobbi De Souza, P. V., Souza, M. N., Osman, S., Baltzer, V., Pacheco Mosquera, L. F., Dubroja, I., Hucika, Z., Lisak, M., Lovrencic-Huzjan, A., Lusic, I., Mahovic Lakusic, D., Mikulenka, P., Rehulka, P., Amin, F. M., Antic, S., Fakhril-Din, Z., Moeller-Hansen, J., Munksgaard, S., Nan, A. M., Pellesi, L., Schytz, H., Vides, M., Braschinsky, K., Krikmann, U., Roos, C., Cauchie, A., Christian, L., Guegan-Massardier, E., Demarquay, G., Gilles, G., Mawet, J., Kuhn, E., Lanteri Minet, M., Bustuchina Vlaicu, M., Moisset, X., Muresan, M., Najjar-Ravan, M., Giraud, P., Simonin, S., De Gaalon, S., Chakhava, G., Demuria, M., Gegelashvili, G., Kapanadze, N., Antonakakis, A., Gaul, C., Forderreuther, S., Huhn, J. -I., Ibragimov, S., Kamm, K., Raffaelli, B., Czaniera, R., Ruscheweyh, R., Gavanozi, E., Karagiorgis, G., Mavridism, T., Ertsey, C., Shubham, D., Callista Tanowi, A. D., Erdana Putra, S., Hadi, D. W., Kurnia, L., Nasrul, M., Albanese, M., Antonaci, F., Asioli, G. M., Baschi, R., Bentivegna, E., Brunelli, N., Caratozzolo, S., Catarci, T., Cherchi, A., Corbelli, I., Costa, A., De Luca, C., Doretti, A., Favoni, V., Ghiotto, N., Giamberardino, M. A., Giani, L., Zanchin, G., Govone, F., Grillo, G., Mampreso, E., Negro, A., Ornello, R., Pasculli, M., Pensato, U., Prudenzano, M. P. A., Quintana, S., Rapisarda, R., Romoli, M., Russo, A., Russo, M., Spuntarelli, V., Tiseo, C., Torrente, A., Vacca, A., Vaula, G., Vigano, A., Vigneri, S., Freimane, A., Slosberga, E., Zvaune, L., Tan, H. J., Fenech, C., Cobilt-Catana, R., De La Garza Neme, Y., Martinez, M., Proano Narvaez, J. V., Rodriguez Herrera, A., Vazquez, D., Grosu, O., Jakupi, A., Kristoffersen, E. S., Tronvik, E., Winsvold, B. S., Azhar, M., Reyes Alvarez, M. T., Vilchez Fernandez, L., Dayrit, G. D., Czapinska-Ciepiela, E. K., Fila, M., Gryglas-Dworak, A., Couto, M., Esperanca, P., Ferreira, A., Gil-Gouveia, R., Goncalves, A., Lopes, M., Lourenco, M., Machado, J., Marinho, M., Miranda, M. A., Palavra, F., Parreira, E., Pavao Martins, I., Pereira, L., Pereira Monteiro, J. M., Leahu, P., Aloman, S., Abramova, E., Akhmadeeva, L., Belopasova, A., Bogdanova, I., Chernyak, M., Epifanova, M., Fedorova, E., Felbush, A., Karpova, M., Korobkova, D., Korotkova, D., Latysheva, N., Makeeva, T., Mikhalkina, K., Osipova, V., Roshchina, O., Serga, A., Serousova, O. V., Sidorova, Y., Skiba, I., Skorobogatykh, K., Vashchenko, N., Apostolski, S., Buder, N., Kopitovic, A., Mirjana, J., Podgorac, A., Rakic, D., Simic, S., Zarko, M., Trajkovic, J. Z., Beltran-Blasco, I., Calabria Gallego, M. D., Diaz Insa, S., Ezpeleta, D., Fernandez, M., Garcia-Azorin, D., Gonzalez-Garcia, N., Guerrero, A. L., Guillamon, E., Herreros Rodriguez, J., Layos-Romero, A., Medrano, V., Minguez-Olaondo, A., Navarro Munoz, S., Pare Curell, M., Ruibal, M., Sanchez Alvarez, J. M., Santos, S., Soler, R., Viguera, J., Zabalza, R., Abdelrahman, T., Abobaker Hamza, S. B., Mustafa, M. N., Edvinsson, L., Gantenbein, A., Maraffi, I., Couturier, E., Dirkx, T., Hoebert, M., Van Oosterhout, W., Wim, M., Zwartbol, R., Bakir, M., Demirel, H., Erdemoglu, A. K., Ertem, D. H., Gonullu, S., Ilgaz Aydinlar, E., Inan, L. E., Olmez, B., Ozbenli, T., Ozge, A., Uluduz, D., Uyar Cankay, T., Yalinay Dikmen, P., Saxena, A. B., Bozhenko, M., Bozhenko, N., Bubnov, R., Tsurkalenko, O., Abu-Arafeh, I., Idrovo, L., Miller, S., Nirmalananthan, N., Sinclair, A., Taleti, E., Valori, A., Whitehouse, W., Zermansky, A., Thura, M., and Internal Medicine

Subjects
Investigative Techniques::Epidemiologic Methods::Data Collection::Surveys and Questionnaires [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], medicine.medical_specialty, Pediatrics, Neurology, Consensus, enfermedades del sistema nervioso::enfermedades del sistema nervioso central::enfermedades cerebrales::trastornos con cefaleas::cefaleas primarias::trastornos migrañosos [ENFERMEDADES], migraine, migraine care, refractory migraine, resistant migraine, consensus, cross-sectional studies, headache, humans, surveys and questionnaires, migraine disorders, Pain medicine, Moderate confidence, Migraine Disorders, Medizin, Consensu, Migranya - Tractament, Qüestionaris, Refractory, Surveys and Questionnaires, medicine, Surveys and Questionnaire, Humans, Clinical significance, Nervous System Diseases::Central Nervous System Diseases::Brain Diseases::Headache Disorders::Headache Disorders, Primary::Migraine Disorders [DISEASES], Otros calificadores::/terapia [Otros calificadores], Migraine, Cross-Sectional Studie, business.industry, Headache, técnicas de investigación::métodos epidemiológicos::recopilación de datos::encuestas y cuestionarios [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], General Medicine, Other subheadings::/therapy [Other subheadings], medicine.disease, Refractory migraine, Anesthesiology and Pain Medicine, Cross-Sectional Studies, Burden, Medicine, Neurology (clinical), Level of care, business, Resistant migraine, Migraine care, Human, Research Article
Abstract

Background New treatments are currently offering new opportunities and challenges in clinical management and research in the migraine field. There is the need of homogenous criteria to identify candidates for treatment escalation as well as of reliable criteria to identify refractoriness to treatment. To overcome those issues, the European Headache Federation (EHF) issued a Consensus document to propose criteria to approach difficult-to-treat migraine patients in a standardized way. The Consensus proposed well-defined criteria for resistant migraine (i.e., patients who do not respond to some treatment but who have residual therapeutic opportunities) and refractory migraine (i.e., patients who still have debilitating migraine despite maximal treatment efforts). The aim of this study was to better understand the perceived impact of resistant and refractory migraine and the attitude of physicians involved in migraine care toward those conditions. Methods We conducted a web-questionnaire-based cross-sectional international study involving physicians with interest in headache care. Results There were 277 questionnaires available for analysis. A relevant proportion of participants reported that patients with resistant and refractory migraine were frequently seen in their clinical practice (49.5% for resistant and 28.9% for refractory migraine); percentages were higher when considering only those working in specialized headache centers (75% and 46% respectively). However, many physicians reported low or moderate confidence in managing resistant (8.1% and 43.3%, respectively) and refractory (20.7% and 48.4%, respectively) migraine patients; confidence in treating resistant and refractory migraine patients was different according to the level of care and to the number of patients visited per week. Patients with resistant and refractory migraine were infrequently referred to more specialized centers (12% and 19%, respectively); also in this case, figures were different according to the level of care. Conclusions This report highlights the clinical relevance of difficult-to-treat migraine and the presence of unmet needs in this field. There is the need of more evidence regarding the management of those patients and clear guidance referring to the organization of care and available opportunities.

Published
2021
Full Text
View/download PDF

24. InterMiG: international differences in the therapeutic approach to migraine patients in specialized headache centers

Author

Gago-Veiga, A. B., Huhn, J-I, Latysheva, N., Vieira Campos, A., Torres-Ferrus, Marta, Alpuente, Alicia, Sacco, Simona, Frattale, I, Ornello, R., Ruscheweyh, Ruth, Marques, I. B., Gryglas-Dworak, A., Stark, C., Gallardo, Víctor J., Pozo-Rosich, Patricia, Universitat Autònoma de Barcelona, Institut Català de la Salut, [Gago-Veiga AB, Vieira Campos A] Headache Unit, Department of Neurology, La Princesa Research Institute. Hospital Universitario de la Princesa, Madrid, Spain. [Huhn JI] Praxis Gendolla. Zentrum für Neurologie und Schmerztherapie, Essen, Germany. [Latysheva N] Department of Neurology, Institute for Professional Education, I.M.Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia. [Torres-Ferrus M, Alpuente Ruiz A, Gallardo VJ, Pozo-Rosich P] Unitat de Cefalees, Servei de Neurologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca en Cefalees i Dolors Neurològics, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Male, Therapeutic algorithm, Antidepressant, Other subheadings::Other subheadings::/drug therapy [Other subheadings], Medicina - Estudi de casos, Beta-blockers, 0302 clinical medicine, Antiepileptic, Medicine, Differences, International, Migraine, OnabotulinumtoxinA, Preventive treatment, Adult, Australia, Female, Headache, Humans, Italy, Middle Aged, Prospective Studies, Retrospective Studies, Spain, Migraine Disorders, Nervous System Diseases::Central Nervous System Diseases::Brain Diseases::Headache Disorders::Headache Disorders, Primary::Migraine Disorders [DISEASES], 030503 health policy & services, General Medicine, 0305 other medical science, Research Article, medicine.medical_specialty, enfermedades del sistema nervioso::enfermedades del sistema nervioso central::enfermedades cerebrales::trastornos con cefaleas::cefaleas primarias::trastornos migrañosos [ENFERMEDADES], Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Migranya - Tractament, 03 medical and health sciences, Therapeutic approach, Internal medicine, business.industry, Mean age, medicine.disease, Anesthesiology and Pain Medicine, técnicas de investigación::métodos epidemiológicos::características de los estudios epidemiológicos::estudios epidemiológicos::estudios de casos y controles::estudios retrospectivos [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Neurology (clinical), Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics::Epidemiologic Studies::Case-Control Studies::Retrospective Studies [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], business, 030217 neurology & neurosurgery
Abstract

Background There is currently a wide therapeutic arsenal for migraine patients, without a single first-line preventive drug and we choose the different available alternatives taking into account comorbidities, national guidelines, previous treatments and personal experiences. Our objective was to evaluate the differences in the use of migraine treatments between neurologists from different countries. Methods This is a multi-centre observational study carried out by neurologists from specialized headache units in seven countries, retrospective with consecutive inclusion of all patients presenting with a migraine diagnosis, over a period of three months. Results A total of 734 patients were recruited but only 600 were considered in the analysis in order to homogenize the patient cohorts from countries: 200 Spain (ES), 100 Italy (IT), 85 Russia (RUS), 80 Germany (DE), 60 Portugal (PT), 45 Poland (PL) and 30 Australia (AU). 85.4 % of patients were women with a mean age of 42.6 ± 11.8 years. Considering previous and current preventive treatment, the order of use was: antidepressants (69.3 %), antiepileptic drugs (54.7 %), beta-blockers and antihypertensive drugs (49.7 %), OnabotulinumtoxinA (44.0 %) and others (36.2 %). Statistically significant differences were found between all pharmacological classes: antidepressants were commonly used in all countries, with the exception of Poland (AU: 76.7 %, IT: 71.0 %, DE: 60.0 %, PL: 31.1 %, PT: 71.7 %, RUS: 70.6 %, ES: 78.5 %; p p p p p Conclusions There is heterogeneity in the choice of preventive treatment between different countries. Prospective comparative studies of the different oral and subcutaneous alternatives would help to create a global therapeutic algorithm that would guarantee the best option for our patients.

Published
2021

25. InterMiG : international differences in the therapeutic approach to migraine patients in specialized headache centers

Author

Gago-Veiga, AB, Huhn, J-I, Latysheva, N, Vieira Campos, A., Torres-Ferrus, Marta, Alpuente Ruiz, A., Sacco, Simona, Frattale, I, Ornello, R, Ruscheweyh, Ruth, Marques, IB, Gryglas-Dworak, A, Stark, C, Gallardo, Víctor J, Pozo-Rosich, Patricia, Universitat Autònoma de Barcelona, Gago-Veiga, AB, Huhn, J-I, Latysheva, N, Vieira Campos, A., Torres-Ferrus, Marta, Alpuente Ruiz, A., Sacco, Simona, Frattale, I, Ornello, R, Ruscheweyh, Ruth, Marques, IB, Gryglas-Dworak, A, Stark, C, Gallardo, Víctor J, Pozo-Rosich, Patricia, and Universitat Autònoma de Barcelona

Abstract

There is currently a wide therapeutic arsenal for migraine patients, without a single first-line preventive drug and we choose the different available alternatives taking into account comorbidities, national guidelines, previous treatments and personal experiences. Our objective was to evaluate the differences in the use of migraine treatments between neurologists from different countries. This is a multi-centre observational study carried out by neurologists from specialized headache units in seven countries, retrospective with consecutive inclusion of all patients presenting with a migraine diagnosis, over a period of three months. A total of 734 patients were recruited but only 600 were considered in the analysis in order to homogenize the patient cohorts from countries: 200 Spain (ES), 100 Italy (IT), 85 Russia (RUS), 80 Germany (DE), 60 Portugal (PT), 45 Poland (PL) and 30 Australia (AU). 85.4 % of patients were women with a mean age of 42.6 ± 11.8 years. Considering previous and current preventive treatment, the order of use was: antidepressants (69.3 %), antiepileptic drugs (54.7 %), beta-blockers and antihypertensive drugs (49.7 %), OnabotulinumtoxinA (44.0 %) and others (36.2 %). Statistically significant differences were found between all pharmacological classes: antidepressants were commonly used in all countries, with the exception of Poland (AU: 76.7 %, IT: 71.0 %, DE: 60.0 %, PL: 31.1 %, PT: 71.7 %, RUS: 70.6 %, ES: 78.5 %; p < 0.0001); antiepileptic drugs were more frequently prescribed in Portugal, Australia and Spain (AU: 73.3 %, IT: 40.0 %, DE: 37.5 %, PL: 48.9 %, PT: 85.0 %, RUS: 29.4 % and ES: 69.0 %; p < 0.0001); beta-blockers and antihypertensive drugs were frequently used in all countries except Italy (AU: 60.0 %, IT: 14.0 %, DE: 53.8 %, PL: 48.9 %, PT: 68.3 %, RUS: 49.4 % and ES: 59.0 %; p < 0.0001); BTX-A were predominately used in Spain, Italy and Australia (AU:56.7 %, IT:58.0 %, DE:20.0 %, PL: 42.2 %, PT: 26.7 %, RUS: 24.7 % and ES: 58.5 %

Published
2021

26. Etiology of 'Sinus Headache'-Moving the Focus from Rhinology to Neurology. A Systematic Review

Author

Paolo Martelletti, Marcin Straburzyński, Eliza Brożek-Mądry, Anna Gryglas-Dworak, and Magdalena Nowaczewska

Subjects
Rhinology, medicine.medical_specialty, Pediatrics, Neurology, sinusitis, Review, lcsh:RC321-571, 03 medical and health sciences, 0302 clinical medicine, Pharmacotherapy, medicine, migraine, Facial pain, midfacial segment pain, 030223 otorhinolaryngology, Sinusitis, lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry, Sinus (anatomy), business.industry, General Neuroscience, medicine.disease, tension-type headache, sinus headache, medicine.anatomical_structure, facial pain, Migraine, Etiology, business, 030217 neurology & neurosurgery
Abstract

‘Sinus headache and/or facial pain’ (SH) is a common complaint encountered by otorhinolaryngologists, neurologists and general practitioners. However, several studies suggested that the majority of those cases may be attributed to primary headaches (i.e., migraine and tension-type headache (TTH). The purpose of this review is to evaluate the etiology of SH. The first part includes cross-sectional studies analyzing the prevalence of respective diagnoses in subjects with SH. The majority of these publications indicate that migraine and TTH are the most prevalent causes of SH, although most of these studies were conducted in a clinical setting. The second part of this review included treatment trials in subjects with SH. The findings from this part of the review show that SH without rhinosinusitis responds well to pharmacotherapy targeted at primary headaches. This observation further supports a neurologic etiology of the majority of SH cases.

Published
2020

27. InterMiG: international differences in the therapeutic approach to migraine patients in specialized headache centers

Author

Gago-Veiga, AB, primary, Huhn, J-I, additional, Latysheva, N, additional, Vieira Campos, A, additional, Torres-Ferrus, M, additional, Alpuente Ruiz, A, additional, Sacco, S, additional, Frattale, I, additional, Ornello, R, additional, Ruscheweyh, R, additional, Marques, IB, additional, Gryglas-Dworak, A, additional, Stark, C, additional, Gallardo, VJ, additional, and Pozo-Rosich, P, additional

Published
2021
Full Text
View/download PDF

28. Wear-Off of OnabotulinumtoxinA Effect Over the Treatment Interval in Chronic Migraine: A Retrospective Chart Review With Analysis of Headache Diaries

Author

Patricia Pozo-Rosich, N. V. Latysheva, Ilaria Frattale, Marta Torres Ferrus, Bal Athwal, Anna Gryglas-Dworak, Catherine D Stark, Simona Sacco, Raffaele Ornello, and Ruth Ruscheweyh

Subjects
Adult, Male, medicine.medical_specialty, Time Factors, botulinum toxin, chronic migraine, OnabotulinumtoxinA, time course, treatment cycle, wear-off, Migraine Disorders, Treatment interval, Placebo, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Chronic Migraine, Quality of life, Regression toward the mean, Internal medicine, Chart review, Outcome Assessment, Health Care, medicine, Humans, 030212 general & internal medicine, Botulinum Toxins, Type A, Aged, Retrospective Studies, business.industry, Middle Aged, Individual level, Botulinum toxin, Diaries as Topic, Neurology, Neuromuscular Agents, Chronic Disease, Female, Neurology (clinical), business, 030217 neurology & neurosurgery, medicine.drug
Abstract

OBJECTIVE To quantify wear-off of the response to OnabotulinumtoxinA (OnabotA) treatment over the treatment cycle in chronic migraine at group and individual level. BACKGROUND OnabotA administered quarterly is an effective treatment for chronic migraine. However, some patients report that headache recurs before the scheduled follow-up injection. METHODS In this retrospective chart review performed in 6 university outpatient centers or private practices specialized in headache treatment, 112 patients with a ≥30% response to OnabotA who completed headache diaries over 13 weeks after OnabotA treatment were included (age [mean ± SD] 45 ± 12 years, 82% female, headache days/month at baseline 24 ± 6). RESULTS Compared to weeks 5 to 8 after injection, headache days/week increased significantly in weeks 12 (+0.52 ± 1.96, 95% CI [0.15, 0.88], P

Published
2020

30. Wear‐Off of OnabotulinumtoxinA Effect Over the Treatment Interval in Chronic Migraine: A Retrospective Chart Review With Analysis of Headache Diaries

Author

Ruscheweyh, Ruth, primary, Athwal, Bal, additional, Gryglas‐Dworak, Anna, additional, Frattale, Ilaria, additional, Latysheva, Nina, additional, Ornello, Raffaele, additional, Pozo‐Rosich, Patricia, additional, Sacco, Simona, additional, Torres Ferrus, Marta, additional, and Stark, Catherine D., additional

Published
2020
Full Text
View/download PDF

32. The midfacial segment pain: little known disorder in need of scientific evaluation.

Author

Straburzyński M, M Agius A, Boczarska-Jedynak M, Brożek-Mądry E, Dżaman K, Gradek-Kwinta E, Gryglas-Dworak A, Nowaczewska M, Sama A, Smardz J, Tsang HK, Więckiewicz M, and Waliszewska-Prosół M

Subjects
Humans, Facial Pain diagnosis, Tension-Type Headache
Abstract

Despite its inclusion in the International Classification of Orofacial Pain, tension-type orofacial pain has little support in the scientific literature. However, a similar-in-phenotype orofacial pain perceived in the middle segment of the face has been described by few case series from mostly ear, nose and throat clinics. The authors of these descriptions used the term 'midfacial segment pain'. Patients had no significant sinonasal disorder in these studies, but experienced symmetrical pain perceived mostly over the maxillary and ethmoid sinuses. No aura or autonomic symptoms were present apart from mild nasal congestion or rhinorrhoea in some individuals. This description appears similar to tension-type headache, but with midfacial location. In this viewpoint, we indicate a need to fill this gap in scientific knowledge and propose a multicentre interdisciplinary study that would give a detailed description of this type of orofacial pain., Competing Interests: Declaration of conflicting interestsThe authors declare that there are no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results